Combination therapy doubles survival in metastatic lung cancer

The immunotherapy drug pembrolizumab, combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to chemotherapy alone, according to an international, Phase III clinical trial.

This post was syndicated from Top Health News -- ScienceDaily. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply